Welcome to our dedicated page for Inmed Pharmaceuticals SEC filings (Ticker: INM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page compiles U.S. Securities and Exchange Commission (SEC) filings for InMed Pharmaceuticals Inc. (NASDAQ: INM), a British Columbia–incorporated pharmaceutical drug development company. These documents provide detailed information on InMed’s proprietary small molecule drug candidates targeting CB1/CB2 receptors, its Alzheimer’s, ocular and dermatological programs, and the commercial activities of its rare cannabinoid subsidiary BayMedica.
Through periodic and current reports, investors can review InMed’s audited and unaudited consolidated financial statements, management’s discussion and analysis, and segment information covering both pharmaceutical development and BayMedica’s commercial operations. Filings such as annual reports on Form 10-K and quarterly reports on Form 10-Q describe sales from BayMedica, research and development spending on programs like INM-901 and INM-089, general and administrative expenses and cash resources.
Current reports on Form 8-K document material events, including financial result announcements, progress updates on INM-901 pharmacokinetic and preclinical studies, legislative developments affecting BayMedica’s rare cannabinoid business, board appointments, and details of private placements and equity purchase agreements. Proxy materials such as the definitive proxy statement on Schedule 14A outline the agenda for the annual general and special meeting of shareholders, including director elections, auditor appointments and share issuance proposals under a Standby Equity Purchase Agreement.
On Stock Titan, these SEC filings are paired with AI-powered summaries that highlight key points, helping readers quickly understand complex disclosures such as multi-segment financials, capital structure changes and regulatory risk discussions. Users can monitor real-time updates from EDGAR, review historical filings across multiple years and examine items related to governance, such as board composition and auditor approvals, all in one organized view for INM.
InMed Pharmaceuticals Inc. filed a prospectus supplement and related prospectus on April 3, 2026 for the sale of its common shares under an existing At The Market Offering Agreement with H.C. Wainwright & Co., LLC. These potential sales are made pursuant to a shelf registration statement on Form S-3, which was filed on March 20, 2026 and declared effective on March 30, 2026.
The company also filed a legal opinion from Norton Rose Fulbright Canada LLP as Exhibit 5.1 covering the legality of the common shares issuable under the Sales Agreement and included a related consent as Exhibit 23.1.
InMed Pharmaceuticals Inc. is offering up to $1,213,648 of its common shares in an at-the-market offering through H.C. Wainwright & Co., acting as sales agent or principal.
The prospectus supplement states a 3.0% sales commission to Wainwright, reports a public float of $3,640,946 (based on non-affiliate holdings as of April 1, 2026), and shows 3,314,063 shares outstanding prior to this offering. The document also discloses a Nasdaq minimum bid-price notice and the wind down of BayMedica’s commercial operations with estimated severance and related costs.
InMed Pharmaceuticals received a Nasdaq notice that its common share closing bid price was below the $1.00 minimum for 30 consecutive trading days from February 11 to March 26, 2026, putting it out of compliance with Nasdaq Listing Rule 5550(a)(2).
The company has 180 calendar days from March 27, 2026 to regain compliance by having its closing bid at or above $1.00 for at least 10 consecutive business days. During this period, its shares will continue trading on the Nasdaq Capital Market under the symbol INM if other listing standards are met.
If InMed cannot meet the requirement within this window, it may qualify for an additional 180-day grace period, potentially using a reverse stock split to lift the share price. Failure to comply after the available periods could lead to delisting, though InMed could appeal to a Nasdaq Hearings Panel.
InMed Pharmaceuticals reported new preclinical results for its INM-901 Alzheimer's disease program, showing positive effects in 3D human brain organoid models of neuroinflammation. In these human tissue-like systems, INM-901 produced dose-dependent reductions in key pro-inflammatory markers such as IL-6 and IL-8.
The anti-inflammatory effects in human organoids were consistent with earlier in vivo Alzheimer's models and ex vivo LPS-induced neuroinflammation studies, supporting translation from animals to human-relevant systems. The company plans a pre-IND meeting with the FDA in Q3 2026 and is targeting an IND submission and Phase 1 trial initiation in 2027, subject to regulatory feedback and completion of IND-enabling work.
$50,000,000 registration: InMed Pharmaceuticals Inc. has filed a shelf prospectus to offer and sell, from time to time, up to $50,000,000 of common shares, preferred shares, warrants, subscription rights and units, in one or more offerings. The prospectus permits sales in any combination and contemplates sales through underwriters, dealers, agents or directly on a continuous or delayed basis.
The filing states the aggregate market value of common shares held by non-affiliates was approximately $2.6 million based on March 18, 2026 closing price of $0.88 and 2,915,074 non-affiliate shares. The audit reports for fiscal years ended June 30, 2025 and June 30, 2024 include explanatory going-concern paragraphs.
InMed Pharmaceuticals Inc. outlines its 2026 pharmaceutical development outlook, focusing on two small molecule drug candidates targeting CB1/CB2 receptors. The lead program, INM-901 for Alzheimer’s disease, has generated preclinical data suggesting anti-neuroinflammatory, neuroprotective and neuritogenic effects, along with oral bioavailability and supportive molecular findings.
The company plans a pre-IND meeting with the U.S. Food and Drug Administration for INM-901 in Q3 2026 and aims to complete IND-enabling studies ahead of a targeted Phase 1 clinical trial start in 2027. A second candidate, INM-089 for dry age-related macular degeneration, is progressing through preclinical work, with a planned FDA pre-IND meeting in Q4 2026.
InMed Pharmaceuticals is winding down the commercial operations of its BayMedica subsidiary in response to expected U.S. legislation (H.R. 5371) that would materially harm BayMedica’s rare cannabinoid business. BayMedica is the company’s only revenue-generating commercial segment.
The wind down is expected to be substantially completed by June 30, 2026, with operations continuing in the interim to sell existing products. BayMedica anticipates severance and employee-related costs of about $550,000 and other related expenditures of about $120,000, partly offset by remaining product profits.
After the exit, InMed plans to focus exclusively on its pharmaceutical pipeline, including drug candidates INM-901 for Alzheimer’s disease and INM-089 for dry age-related macular degeneration. Unaudited pro forma financials reclassify BayMedica’s business as discontinued operations.
InMed Pharmaceuticals reported second quarter fiscal 2026 results and updated progress across its neurology and ophthalmology drug pipeline. BayMedica commercial revenue was $0.8 million, down from $1.1 million a year earlier, mainly due to pending U.S. legislation that may restrict rare, non-intoxicating cannabinoids.
The company recorded a quarterly net loss of $2.0 million, improving from a $2.6 million loss last year, as research and development expenses fell to $0.6 million from $0.9 million and general and administrative costs eased slightly. As of December 31, 2025, cash, cash equivalents and short-term investments totaled $7.0 million, down from $11.1 million at fiscal year-end, and are expected to fund operations into the fourth quarter of calendar 2026.
Lead candidate -901 for Alzheimer’s disease showed robust oral bioavailability and no adverse neurological effects in large-animal studies, supporting plans for GLP-enabling work and an IND submission. Dry AMD candidate -089 continues to deliver functional and pathological improvements in preclinical models. However, U.S. Act H.R. 5371 could prohibit key BayMedica products from November 12, 2026, potentially forcing inventory write-offs or even discontinuation of BayMedica’s business, which the company warns would have a material adverse effect on its operations and financial condition.
InMed Pharmaceuticals Inc. reported lower commercial revenue and continuing losses for the three and six months ended December 31, 2025, while flagging substantial doubt about its ability to continue as a going concern. BayMedica’s rare‑cannabinoid business faces potential prohibition under new U.S. legislation, which could force inventory write‑offs or exit. The company also highlighted an arbitration over a technology license where the counterparty is seeking significant royalty payments, noting that an unfavorable outcome could materially harm its financial condition and BayMedica’s operations.